Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Wanner

Showing results (351-360 of 785) with videos related to

Pageof 79
Sort By:
Journal of Diabetes and Its Complications|March 1, 2023
Design and rationale of FINE-REAL: A prospective study of finerenone in clinical practiceNihar R Desai, Sankar D Navaneethan, Susanne B Nicholas, et al.
Circulation|September 4, 2003
Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging studyFrank Weidemann, Frank Breunig, Meinrad Beer, et al.
Kidney International|February 5, 2019
A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patientsFabian Hammer, Uwe Malzahn, Julian Donhauser, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 19, 2009
Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populationsBjörn Oqvist, Barry M Brenner, João Paulo Oliveira, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 16, 2010
Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD studyChristiane Drechsler, Marion Verduijn, Stefan Pilz, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 14, 2012
Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best PracticeWim Terryn, Pierre Cochat, Roseline Froissart, et al.
Clinical Therapeutics|October 4, 2016
Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 DiabetesTim Heise, Jens Jordan, Christoph Wanner, et al.
Cardiovascular Diabetology|July 11, 2024
Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trialDavid Fitchett, Bernard Zinman, Silvio E Inzucchi, et al.
Journal of Diabetes and Its Complications|September 18, 2022
Chronic kidney disease and cognitive decline in patients with type 2 diabetes at elevated cardiovascular riskChloë Verhagen, Jolien Janssen, Crista A Minderhoud, et al.
Clinical Kidney Journal|August 14, 2024
Reduction in kidney function decline and risk of severe clinical events in agalsidase beta-treated Fabry disease patients: a matched analysis from the Fabry RegistryJulie L Batista, Ali Hariri, Manish Maski, et al.
Pageof 79

Showing results (351-360 of 785) with videos related to

Sort By:
Pageof 79
Journal of Diabetes and Its Complications|March 1, 2023
Design and rationale of FINE-REAL: A prospective study of finerenone in clinical practiceNihar R Desai, Sankar D Navaneethan, Susanne B Nicholas, et al.
Circulation|September 4, 2003
Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging studyFrank Weidemann, Frank Breunig, Meinrad Beer, et al.
Kidney International|February 5, 2019
A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patientsFabian Hammer, Uwe Malzahn, Julian Donhauser, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 19, 2009
Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populationsBjörn Oqvist, Barry M Brenner, João Paulo Oliveira, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 16, 2010
Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD studyChristiane Drechsler, Marion Verduijn, Stefan Pilz, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 14, 2012
Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best PracticeWim Terryn, Pierre Cochat, Roseline Froissart, et al.
Clinical Therapeutics|October 4, 2016
Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 DiabetesTim Heise, Jens Jordan, Christoph Wanner, et al.
Cardiovascular Diabetology|July 11, 2024
Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trialDavid Fitchett, Bernard Zinman, Silvio E Inzucchi, et al.
Journal of Diabetes and Its Complications|September 18, 2022
Chronic kidney disease and cognitive decline in patients with type 2 diabetes at elevated cardiovascular riskChloë Verhagen, Jolien Janssen, Crista A Minderhoud, et al.
Clinical Kidney Journal|August 14, 2024
Reduction in kidney function decline and risk of severe clinical events in agalsidase beta-treated Fabry disease patients: a matched analysis from the Fabry RegistryJulie L Batista, Ali Hariri, Manish Maski, et al.
Pageof 79